Mauna Kea Technologies welcomes Jacquelien Ten Dam to its Board as Independent Director

– FRANCE, Paris –  Mauna Kea Technologies (EPA: MKEA | OTC: MKEAY) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy platform, today announced the cooptation of Jacquelien Ten Dam to its Board as an Independent Director, effective immediately. replacing Dr. Jennifer Tseng, who tendered her resignation from the Board after 3 years of service.

“I am pleased to welcome Jacquelien to the Board, where she will bring more than a decade of experience advising, financing and leading innovative European healthcare firms. Jacquelien’s expertise will be important as the Company accelerates the commercialization of the Cellvizio platform and executes on its strategic roadmap.” said Founder and Board Chairman, Dr. Sacha Loiseau.

He added: “On behalf of the Board of Directors, I would like to thank Jennifer for her important contribution to the Mauna Kea Board,” said Founder and Board Chairman, Dr. Sacha Loiseau. “It has been a pleasure to work with Jennifer and we have benefitted greatly from her expertise as a surgeon and clinical leader.”

About Jacquelien Ten Dam

Ms. Ten Dam currently serves as the CFO of Mimetas, a biotech company based in The Netherlands.

Jacquelien Ten Dam studied Biomedical Sciences before joining Kempen, a leading European investment bank, where she advised life science firms on strategy, M&A and capital market transactions. After a stint at Picnic, a start-up company in the digital retail industry, Jacquelien joined Mimetas as CFO. Mimetas develops and commercializes 3D predictive models for drug discovery.

“My experience with Mauna Kea precedes the Company’s 2011 IPO and I remain impressed with the far-reaching potential of Cellvizio to improve patient care and advance science,” commented Jacquelien Ten Dam. “I look forward to contributing to the Company’s next phase of value creation for Mauna Kea shareholders.”

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio, has received clearance/approval for a wide range of applications in the United States and more than 40 countries around the World.

For more information : https://www.maunakeatech.com/en/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.